Product Description
Masitinib is an orally available inhibitor of the protein tyrosine kinase c-kit, which is expressed on cancer cells. Masitinib also inhibits PDGF and FGF receptors, and fyn and lyn kinases (Dubreuil et al., 2009).
Mechanisms of Action: PK Inhibitor,TK Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Orphan Drug - Amyotrophic Lateral Sclerosis *
Approval Status: Not Approved
Approved Countries: Austria | European Medicines Agency | Poland
Approved Indications: None
Known Adverse Events: None
Company: AB Science
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Denmark, France, Germany, Greece, Hong Kong, Israel, Italy, Korea, Moldova, Netherlands, New Zealand, Norway, Poland, Romania, Russia, Slovenia, South Africa, Spain, Sweden, Ukraine, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 17
Highest Development Phases
Phase 3: Adenocarcinoma|Alzheimer Disease|Amyotrophic Lateral Sclerosis|Colorectal Cancer|Esophageal Cancer|Gastrointestinal Cancer|Mastocytosis, Systemic|Multiple Sclerosis|Multiple Sclerosis, Chronic Progressive
Phase 2: COVID-19|Depressive Disorder|Intestinal Diseases|Mastocytosis|Pruritus
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| AB21004 | P3 |
Not yet recruiting |
Alzheimer Disease |
2026-12-01 |
31% |
| AB20006 | P2 |
Unknown Status |
Unknown |
2026-03-01 |
|
| MAXIMS | P3 |
Recruiting |
Multiple Sclerosis, Chronic Progressive |
2025-12-01 |
86% |
| 2021-005406-96 | P2 |
Active, not recruiting |
Depressive Disorder|Pruritus |
2025-06-30 |